Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

Intravenous bisphosphonates versus Denosumab for new-onset diabetes

Denosumab and Risk of Type 2 Diabetes Risk Among Patients With Osteoporosis: A Retrospective Cohort Study

Endocrine Practice

Citation & Authors

Endocr Pract. 2026;32(9):1378–1386.

Han CH, Tsai YC, Wang SI, Chang R, Wei JCC.

ABSTRACT · RESEARCH SUMMARY

Research summary

After TriNetX matching, each group contained 20,735 patients with osteoporosis. Compared with denosumab, intravenous bisphosphonates were associated with lower risks of incident type 2 diabetes at 1, 3, 5, and 7 years; the 5-year HR was 0.818 (95% CI 0.747–0.895). The direction favors intravenous bisphosphonates; it should not be misreported as a lower diabetes risk with denosumab.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗

Key findings

After matching, each group included 20,735 patients. Compared with denosumab, intravenous bisphosphonates were associated with a lower risk of incident type 2 diabetes: the 5-year HR was 0.818 (95% CI 0.747–0.895), and the 7-year HR was 0.821 (95% CI 0.753–0.896).

The study compares associations between two treatment strategies; it does not establish that denosumab causes diabetes. Prospective validation is needed.